BioCAST/IFCT-1002: Epidemiological and molecular features of lung cancer in never-smokers

European Respiratory Journal

Volumn 45, Issue 5, 2015, Pages 1403-1414

  Couraud, Sébastien ^a,b,c,d   Souquet, Pierre Jean ^a,b   Paris, Christophe ^e   Dô, Pascal ^f   Doubre, Hélène ^g   Pichon, Eric ^h,i   Dixmier, Adrien ^j   Monnet, Isabelle ^k   Etienne Mastroianni, Bénédicte ^b,l   Vincent, Michel ^m   Trédaniel, Jean ⁿ   Perrichon, Marielle ^o   Foucher, Pascal ^p   Coudert, Bruno ^q   Moro Sibilot, Denis ^r,s   Dansin, Eric ^t   Labonne, Stéphanie ^a,b   Missy, Pascale ^u   Morin, Franck ^u   Blanché, Hélène ^v   Zalcman, Gérard ^w   more..

^a CENTRE HOSPITALIER LYON SUD   (France)

^b UNIVERSITÉ LYON 1   (France)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITÉ DE LORRAINE   (France)

^f Francois Baclesse Cancer Institute   (France)

^g Foch General Hospital   (France)

^h UNIVERSITY HOSPITAL OF TOURS   (France)

ⁱ UNIVERSITÉ DE TOURS   (France)

^j Orleans Regional Hospital   (France)

^k CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^l LOUIS PRADEL HOSPITAL   (France)

^m CENTRE HOSPITALIER SAINT JOSEPH SAINT LUC   (France)

ⁿ SAINT JOSEPH HOSPITAL   (France)

^o Pulmonology Dept Bourg en Bresse General Hospital   (France)

^p DIJON UNIVERSITY HOSPITAL   (France)

^q Georges Francois Leclerc Cancer Center   (France)

^r GRENOBLE UNIVERSITY HOSPITAL   (France)

^s UNIV GRENOBLE ALPES   (France)

^t Oscar Lambret Centre   (France)

^u Intergroupe Francophone de Cancérologie Thoracique Paris   (France)

^v FONDATION JEAN DAUSSET CEPH   (France)

^w CAEN UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; ANAPLASTIC LYMPHOMA KINASE; BIOLOGICAL MARKER; BRAF PROTEIN, HUMAN; CARCINOGEN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; NUCLEAR PROTEIN; PASSIVE SMOKING; PI3KCA PROTEIN, HUMAN; PROTEIN P21; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR;

ADENOCARCINOMA; ADULT; ALK GENE; ARTICLE; BRAF GENE; CONTROLLED STUDY; EGFR GENE; EPIDEMIOLOGICAL DATA; FAMILY HISTORY; FEMALE; GENE; GENE MUTATION; HUMAN; LARGE CELL CARCINOMA; LUNG CANCER; LUNG CANCER IN NEVER SMOKER; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; NON SMALL CELL LUNG CANCER; OBSERVATIONAL STUDY; OCCUPATIONAL CARCINOGENESIS; OCCUPATIONAL EXPOSURE; ONCOGENE K RAS; ONCOGENE NEU; PASSIVE SMOKING; PI3KCA GENE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SARCOMATOID CARCINOMA; SEX DIFFERENCE; SMOKING; AGED; CLINICAL TRIAL; COHORT ANALYSIS; FRANCE; GENETIC PREDISPOSITION; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; OCCUPATIONAL DISEASES; QUESTIONNAIRE;

AGED; BIOMARKERS; CARCINOGENS; COHORT STUDIES; FEMALE; FRANCE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RISK FACTORS; SEX FACTORS; SMOKING; SURVEYS AND QUESTIONNAIRES; TOBACCO SMOKE POLLUTION; TRANSCRIPTION FACTORS;

EID: 84929012516     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00097214     Document Type: Article

References (27)

1. Couraud S, Zalcman G, Milleron B, et al. Lung cancer in never smokers: A review. Eur J Cancer 2012; 48: 1299-1311.
2. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers: A different disease. Nat Rev Cancer 2007; 7: 778-790.
3. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
4. Samet JM, Avila-Tang E, Boffetta P, et al. Lung cancer in never smokers: Clinical epidemiology and environmental risk factors. Clin Cancer Res 2009; 15: 5626-5645.
5. Mounawar M, Mukeria A, Le Calvez F, et al. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history. Cancer Res 2007; 67: 5667-5672.
6. Mazières J, Peters S, Lepage B, et al. Lung cancer that harbors a HER2 mutation: Epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013; 31; 1997-2003.
7. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011; 29: 2046-2051.
8. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27: 4247-4253.
9. Couraud S, Labonne S, Missy P, et al. BioCAST: le Bio-observatoire national du cancer bronchiques chez les patients non fumeurs (IFCT1002). [Lung cancer in never smokers: A French national cohort (BioCAST/IFCT-1002)]. Rev Mal Respir 2013; 30; 576-583.
10. Bourgkard E, Wild P, Gonzalez M, et al. Comparison of exposure assessment methods in a lung cancer case-control study: performance of a lifelong task-based questionnaire for asbestos and PAHs. Occup Environ Med. 2013; 70; 884-891.
11. Nowak F, Soria JC, Calvo F. Tumour molecular profiling for deciding therapy-the French initiative. Nat Rev Clin Oncol 2012; 9: 479-486.
12. Beau-Faller M, Degeorges A, Rolland E, et al. Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: A total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma (ERMETIC) project: part 1). J Thorac Oncol 2011; 6: 1006-1015.
13. Beau-Faller M, Blons H, Domerg C, et al. A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting: IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms. J Mol Diagn 2014; 16: 45-55.
14. Coëtmeur D, Briens E, Perrin C, et al. Lung cancer characteristics in 762 never- And 6, 246 ever-smoker patients: Study KBP-2010-CPHG. J Clin Oncol 2014; 32: Suppl. 15, 1582.
15. Vineis P, Airoldi L, Veglia F, et al. Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study. BMJ 2005; 330: 277.
16. Kim HR, Shim HS, Chung JH, et al. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer 2012; 118: 729-739.
17. Kawaguchi T, Ando M, Kubo A, et al. Long exposure of environmental tobacco smoke associated with activating EGFR mutations in never-smokers with non-small cell lung cancer. Clin Cancer Res 2011; 17: 39-45.
18. Clément-Duchêne C, Vignaud JM, Stoufflet A, et al. Characteristics of never smoker lung cancer including environmental and occupational risk factors. Lung Cancer 2010; 67: 144-150.
19. Lissowska J, Bardin-Mikolajczak A, Fletcher T, et al. Lung cancer and indoor pollution from heating and cooking with solid fuels: The IARC international multicentre case-control study in Eastern/Central Europe and the United Kingdom. Am J Epidemiol 2005; 162: 326-333.
20. Sun Y, Ren Y, Fang Z, et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 2010; 28: 4616-4620.
21. Paik PK, Johnson ML, D'Angelo SP, et al. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. Cancer 2012; 118: 5840-5847.
22. Barlesi F, Blons H, Beau-Faller M, et al. Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10, 000 non-small cell lung cancer (NSCLC) patients ( pts). J Clin Oncol 2013; 31: Suppl. 15, 8000.
23. Machin D, Campbell MJ, Tan S-B, et al. Sample size tables for clinical studies. 3rd Edn. Hoboken, Wiley-Blackwell, 2008.
24. Lee SE, Lee B, Hong M, et al. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma. Mod Pathol 2014; [in press DOI:10.1038/modpathol.2014.107].
25. Kim HR, Lim SM, Kim HJ, et al. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol 2013; 24: 2364-2370.
26. Couraud S, Dumont P, Moreau L, et al. Impact of Passive Smoking on molecular pattern in Never Smokers with Non-Small Cell Lung Cancer: Findings from the BioCAST/IFCT-1002 Study. Abstract#O18.04. J Thorac Oncol 2013; 8: Suppl. 2, S1-S1410.
27. Sisti J, Boffetta P. What proportion of lung cancer in never-smokers can be attributed to known risk factors? Int J Cancer 2012; 131: 265-275.